Association of plasma levels of soluble receptor for advanced glycation end products and risk of kidney disease: The Atherosclerosis Risk in Communities study

Nephrology Dialysis Transplantation

Volumn 30, Issue 1, 2015, Pages 77-83

  Rebholz, Casey M ^a   Astor, Brad C ^b   Grams, Morgan E ^a,c   Halushka, Marc K ^c   Lazo, Mariana ^a,c   Hoogeveen, Ron C ^d   Ballantyne, Christie M ^d   Coresh, Josef ^a,c   Selvin, Elizabeth ^a,c  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

Author keywords

advanced glycation end product receptor; chronic kidney failure; risk factors

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CREATININE; IMMUNOGLOBULIN RECEPTOR;

ADULT; ARTICLE; CHRONIC KIDNEY DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; DIABETES MELLITUS; END STAGE RENAL DISEASE; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PROGNOSIS; PROTEIN BLOOD LEVEL; RACE DIFFERENCE; ATHEROSCLEROSIS; BLOOD; CASE CONTROL STUDY; CLINICAL TRIAL; COMPARATIVE STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; KIDNEY FAILURE, CHRONIC; METABOLISM; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR;

ADVANCED GLYCOSYLATION END PRODUCT-SPECIFIC RECEPTOR; ATHEROSCLEROSIS; BIOMARKERS; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; COHORT STUDIES; CREATININE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PROGNOSIS; RECEPTORS, IMMUNOLOGIC; RISK FACTORS;

EID: 84922422557     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfu282     Document Type: Article

References (36)

1. Goh SY, Cooper ME. Clinical review: the role of advanced glycation end products in progression and complications of diabetes. J Clin Endocrinol Metab 2008; 93: 1143-1152
2. Selvin E, Halushka MK, Rawlings AM et al. sRAGE and risk of diabetes, cardiovascular disease, and death. Diabetes 2013; 62: 2116-2121
3. Henning C, Smuda M, Girndt M et al. Molecular basis of Maillard amideadvanced glycation end product (AGE) formation in vivo. J Biol Chem 2011; 286: 44350-44356
4. Fukami K, Yamagishi S, Okuda S. Role of AGEs-RAGE system in cardiovascular disease. Curr Pharm Des 2014; 20: 2395-2402
5. Yan SF, Ramasamy R, Schmidt AM. Mechanisms of disease: advanced glycation end-products and their receptor in inflammation and diabetes complications. Nat Clin Pract Endocrinol Metab 2008; 4: 285-293
6. Wautier MP, Chappey O, Corda S et al. Activation of NADPH oxidase by AGE links oxidant stress to altered gene expression via RAGE. Am J Physiol Endocrinol Metab 2001; 280: E685-E694
7. Sadik NA, Mohamed WA, Ahmed MI. The association of receptor of advanced glycated end products and inflammatory mediators contributes to endothelial dysfunction in a prospective study of acute kidney injury patients with sepsis. Mol Cell Biochem 2012; 359: 73-81
8. Zhang L, Bukulin M, Kojro E et al. Receptor for advanced glycation end products is subjected to protein ectodomain shedding by metalloproteinases. J Biol Chem 2008; 283: 35507-35516
9. Sarkany Z, Ikonen TP, Ferreira-da-Silva F et al. Solution structure of the soluble receptor for advanced glycation end products (sRAGE). J Biol Chem 2011; 286: 37525-37534
10. Han SH, Kim YH, Mook-Jung I. RAGE: the beneficial and deleterious effects by diverse mechanisms of actions. Mol Cells 2011; 31: 91-97
11. Park L, Raman KG, Lee KJ et al. Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts. Nat Med 1998; 4: 1025-1031
12. Lanati N, Emanuele E, Brondino N et al. Soluble RAGE-modulating drugs: state-of-The-Art and future perspectives for targeting vascular inflammation. Curr Vasc Pharmacol 2010; 8: 86-92
13. Basta G, Leonardis D, Mallamaci F et al. Circulating soluble receptor of advanced glycation end product inversely correlates with atherosclerosis in patients with chronic kidney disease. Kidney Int 2010; 77: 225-231
14. Kalousova M, Hodkova M, Kazderova M et al. Soluble receptor for advanced glycation end products in patients with decreased renal function. Am J Kidney Dis 2006; 47: 406-411
15. Kim JK, Park S, Lee MJ et al. Plasma levels of soluble receptor for advanced glycation end products (sRAGE) and proinflammatory ligand for RAGE (en-RAGE) are associated with carotid atherosclerosis in patients with peritoneal dialysis. Atherosclerosis 2012; 220: 208-214
16. Semba RD, Ferrucci L, Fink JC et al. Advanced glycation end products and their circulating receptors and level of kidney function in older community-dwelling women. Am J Kidney Dis 2009; 53: 51-58
17. The ARIC Investigators. The Atherosclerosis Risk in Communities (ARIC) Study: design and objectives. Am J Epidemiol 1989; 129: 687-702
18. Brown LF, Fraser CG. Assay validation and biological variation of serum receptor for advanced glycation end-products. Ann Clin Biochem 2008; 45: 518-519
19. Wittwer C, Lehner J, Fersching D et al. Methodological and preanalytical evaluation of a RAGE immunoassay. Anticancer Res 2012; 32: 2075-2078
20. Lustgarten JA, Wenk RE. Simple, rapid, kinetic method for serum creatinine measurement. Clin Chem 1972; 18: 1419-1422
21. Inker LA, Schmid CH, Tighiouart H et al. Estimating glomerular filtration rate from serum creatinine and cystatin C. N Engl J Med 2012; 367: 20-29
22. Levey AS, Stevens LA, Schmid CH et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009; 150: 604-612
23. Selvin E, Coresh J, Zhu H et al. Measurement of HbA1c from stored whole blood samples in the Atherosclerosis Risk in Communities Study. J Diabetes 2010; 2: 118-124
24. Warnick GR, Benderson J, Albers JJ. Dextran sulfate-Mg2+ precipitation procedure for quantitation of high-density-lipoprotein cholesterol. Clin Chem 1982; 28: 1379-1388
25. Barlow WE. Robust variance estimation for the case-cohort design. Biometrics 1994; 50: 1064-1072
26. Barlow WE, Ichikawa L, Rosner D et al. Analysis of case-cohort designs. J Clin Epidemiol 1999; 52: 1165-1172
27. Lindsey JB, de Lemos JA, Cipollone F et al. Association between circulating soluble receptor for advanced glycation end products and atherosclerosis: observations from the Dallas Heart Study. Diabetes Care 2009; 32: 1218-1220
28. Hudson BI, Moon YP, Kalea AZ et al. Association of serum soluble receptor for advanced glycation end-products with subclinical cerebrovascular disease: the Northern Manhattan Study (NOMAS). Atherosclerosis 2011; 216: 192-198
29. Nin JW, Jorsal A, Ferreira I et al. Higher plasma soluble receptor for advanced glycation end products (sRAGE) levels are associated with incident cardiovascular disease and all-cause mortality in type 1 diabetes: a 12-year follow-up study. Diabetes 2010; 59: 2027-2032
30. Colhoun HM, Betteridge DJ, Durrington P et al. Total soluble and endogenous secretory receptor for advanced glycation end products as predictive biomarkers of coronary heart disease risk in patients with type 2 diabetes: an analysis from the CARDS trial. Diabetes 2011; 60: 2379-2385
31. Forbes JM, Thorpe SR, Thallas-Bonke V et al. Modulation of soluble receptor for advanced glycation end products by angiotensin-converting enzyme-1 inhibition in diabetic nephropathy. J Am Soc Nephrol 2005; 16: 2363-2372
32. Linden E, Cai W, He JC et al. Endothelial dysfunction in patients with chronic kidney disease results from advanced glycation end products (AGE)-mediated inhibition of endothelial nitric oxide synthase through RAGE activation. Clin J Am Soc Nephrol 2008; 3: 691-698
33. Hartog JWL, De Vries APJ, Lutgers HL et al. Accumulation of advanced glycation end products, measured as skin autofluorescence, in renal disease. Ann N Y Acad Sci 2005; 1043: 299-307
34. Renard C, Chappey O,Wautier MP et al. Recombinant advanced glycation end product receptor pharmacokinetics in normal and diabetic rats. Mol Pharmacol 1997; 52: 54-62
35. Kshirsagar AV, Bomback AS, Bang H et al. Association of C-reactive protein and microalbuminuria (from the National Health and Nutrition Examination Surveys, 1999 to 2004). Am J Cardiol 2008; 101: 401-406
36. Bower JK, Pankow JS, Lazo M et al. Three-year variability in plasma concentrations of the soluble receptor for advanced glycation end products (sRAGE). Clin Biochem 2014; 47: 132-134